ImmuPharma plc · LSE:IMM

ImmuPharma — Investor Presentation (September 2023)

31 slides from ImmuPharma's investor presentation, September 2023

  1. Slide 1: ImmuPharma September 2023

    W ImmuPharma BioPharma | Creation | Evolution September 2023

  2. Slide 2: ImmuPharma Snapshot

    ImmuPharma Snapshot § Listed on UK AIM (LSE:IMM) § Pipeline of innovative peptide-based therapies § 2 therapy areas - Autoimmunity/Inflammation and Anti-infection § 4 core assets & 1 non-core asset for high medical need markets § Lupuzor® (P140) for Lupus (Ph 2/3) § P140 for CIDP (Ph2/3) § BioAMB, a

  3. Slide 3: ImmuPharma Business Model

    ImmuPharma Business Model § Out-license assets at key value inflection points § Minimize in-house development costs § Partners support final development and distribution § Milestone/royalty income streams to ImmuPharma § Therapeutic focus - Autoimmunity/Inflammation and Anti-infection § High medical

  4. Slide 4: Team

    Team 4

  5. Slide 5: New Team

    NEW TEAM Tim McCarthy FCCA, MBA Dr Tim Franklin, PhD, MBA Chief Executive Officer Chief Operating Officer Dr Sebastien Goudreau PhD Lisa Baderoon Chief Executive Officer of ImmuPharma Dr Laurence Reilly MBA Senior Non-Executive Director Non-Executive Director Biotech and Head of Investor Relations 5

  6. Slide 6: ImmuPharma Biotech R&D Unit in Bordeaux

    ImmuPharma Biotech R&D Unit in Bordeaux § A wholly-owned subsidiary of ImmuPharma PLC § Dr Sebastien Goudreau – CEO § Dr Laura Mauran – CSO § Specialising in peptide science and technology § Key focus on developing peptide- enhanced versions of P140, amphotericin-B and vancomycin 6

  7. Slide 7: Prof Sylviane Muller & CNRS

    Prof Sylviane Muller & CNRS § Prof Muller is the discoverer of P140 and scientific advisor to ImmuPharma § Research Director at CNRS (The French National Centre for Scientific Research) & Co-founder of ImmuPharma France § CNRS Laboratory of Therapeutic Immunology and Chemistry at the Institute of Mo

  8. Slide 8: Portfolio & Pipeline

    Portfolio & Pipeline 8

  9. Slide 9: Pipeline

    Pipeline Preclinical Phase I Phase II Phase III Partners *P140 (Lupuzor TM) Lupus *P140 CIDP P140 2.0 Asthma , IBD, Periodiontits, gout BioAMB Fungal infections BioCIN Bacterial infections **IPP-204107 Cancer *Phase 2/3 adaptive study **Radiopharmaceutical Autoimmune/anti-inflammatory Anti-infection

  10. Slide 10: Pipeline Objectives & News Flow 2023

    Pipeline Objectives & News Flow 2023 Autoimmunity & Anti-infection inflammation •Lupus - Type-C FDA meeting for • Complete Bio-AMB (novel Phase 2/3 adaptive study on 7th June amphotericin) efficacy/tox study 2023 ✓ versus voriconazole in Aspergillosis rodent model to realise immediate value inflecti

  11. Slide 11: Autoimmunity & Inflammation: The P140 platform

    Autoimmunity & Inflammation The P140 platform 11

  12. Slide 12: P140 MOA is relevant to several diseases

    P140 MOA is relevant to several diseases § P140 core action is in chaperone-mediated autophagy § P140 binds to the constitutively-expressed HSPA8/HSC70 protein § P140 hampers its chaperone functions in-vitro § P140 reduces HSPA8/HSP90 interaction § Restricts stimulation of autoreactive T cells and c

  13. Slide 13: Lupuzor for Lupus

    LUPUZORTM for Lupus About Lupus LupuzorTM, (P140) is commencing a new phase 2/3 adaptive study in lupus patients in H2 2023 Systemic lupus erythematosus (SLE) is a chronic, life- LupuzorTM, has the potential to be a novel first-line drug threatening autoimmune, inflammatory disease with a therapy fo

  14. Slide 14: SLE Clinical Activity for P140 in 2023

    SLE Clinical Activity for P140 in 2023 § Agreed Phase 2/3 study design with US partner Avion in Jan 2023 § FDA Type-C meeting feedback received – ensured study design § Final approach - higher subcutaneous dosing, once monthly § *Commenced phase 2/3 study activities * Definition is CRO is chosen & f

  15. Slide 15: P140 for CIDP

    1; ImmuPharma BioPharma | Creation | Evolution 4 for CIDP

  16. Slide 16: P140 for CIDP

    P140 for CIDP P140 shows efficacy in *pre-clinical model of Chronic Inflammatory Demyelinating About CIDP Polyneuropathy (“CIDP”) CIDP is neurological autoimmune disease targeting the nerves. P140 MOA on the autoimmune mechanism is Symptoms include: fatigue, areas of numbness, slow reflexes, weaknes

  17. Slide 17: P140 2.0 for autoimmune/inflammatory diseases

    P140 2.0 for autoimmune/inflammatory diseases 17

  18. Slide 18: P140 2.0 is the next generation P140

    P140 2.0 is the next generation P140 § Same active peptide, same MOA § Proprietary peptide-based Bio-Drug engineering § Enhanced PK/PD profile § Easier to administer (dose/frequency), lower absolute amount of drug § New IP and new product life cycle following 1st generation P140 § Allows expansion i

  19. Slide 19: BioAMB for systemic fungal infections

    BioAMB for systemic fungal infections 19

  20. Slide 20: BioAMB for systemic fungal infections

    BioAMB for systemic fungal infections About Anti-Infectives BioAMB is a novel biomodified peptide- based drug that offers a potential Anti-infectives : Increased antibiotic and anti-fungal resistance is improvement on Amphotericin-B (“Amp-B”). one of the biggest threats to global health, cost and mo

  21. Slide 21: BioCIN for severe bacterial infections

    BioCIN for severe bacterial infections 21

  22. Slide 22: BioCIN for severe bacterial infections

    BioCIN for severe bacterial infections BioCIN is a novel biomodified peptide-based drug that offers a potential improvement on Vancomycin About Anti-Infectives Vancomycin, a generic drug, is a last resort Anti-infectives : Increased antibiotic and anti-fungal resistance is therapy for the treatment

  23. Slide 23: IPP-204107 Radiopharmaceutical for cancer

    IPP-204107 Radiopharmaceutical for cancer 23

  24. Slide 24: IPP-204107 a potential breakthrough in cancer

    IPP-204107 a potential breakthrough in cancer § IPP-207107 is a pseudopeptide that binds to a receptor on cancer cells § Transported to the cancer cell nucleus § Previously studied PC and to Phase I § 12-month collaboration with OranoMed (from April 2023) § OranoMed - subsidiary of Orano (multinatio

  25. Slide 25: Company Value

    Company Value A significantly undervalued stock 25

  26. Slide 26: ImmuPharma embedded value

    ImmuPharma embedded value …. § Mid to late-stage clinical pipeline with significant product differentiation § High medical need and commercially attractive markets § Biotech company peers are valued at least 100x higher on average by the markets § Biotech’s with similar stage products valued ~$680-1

  27. Slide 27: Portfolio forecast sales potential of ~$5.5bn

    PORTFOLIO FORECAST SALES POTENTIAL OF ~$5.5bn 3.5 3 2.5 Sales $bn 2 1.5 1 0.5 0 P140-SLE P140-CIDP BioAMB US ROW

  28. Slide 28: Potential News Flow 2023/4

    Potential News Flow 2023/4 § Lupuzor adaptive 2/3 pivotal study activities in lupus *commenced § Regular monthly updates on clinical trial set-up and progress § Positive IND outcome for new CIDP study and orphan drug designation § BioAMB efficacy, safety data and toxicity data versus voriconazole §

  29. Slide 29: ImmuPharma PLC share price is an opportunity

    ImmuPharma PLC share price is an opportunity 200p Lupuzor phase 3 trial design for lupus was flawed. Study 180p failed 160p 140p 120p FDA approve trial but require a Phase 1 PK study prior to 100p starting Phase 3. New P140 synthesis 80p and cheaper manufacturing 60p Analysis of lupus trial Avion de

  30. Slide 30: The last 2 years: getting it right with the FDA

    The last 2 years……getting it right with the FDA Fund raise . Avion Positive data from plus 2 main investors P140 PK study in £3.55m humans FDA Type-C meeting guidance on P140 lupus phase 3 study. Dosing a key point New FDA meetings agreed for lupus(Type-C) and CIDP (Type-B) for *commencement of clin

  31. Slide 31: ImmuPharma undervalued on global peer comparison

    IMMUPHARMA UNDERVALUED ON GLOBAL PEER COMPARISON 2500 2000 Acquisition value $m 1500 ImmuPharma current Mkt Cap = $10m ImmuPharma value range 1000 Peer group range suggests $680m-$1750m 500 0 Pre-clinical Phase I Phase II Phase III Approved The European Journal of Health Economics, Dec 2021

ImmuPharma — Investor Presentation (September 2023) on 6ix